GDTC — CytoMed Therapeutics Income Statement
0.000.00%
Last trade - 00:00
HealthcareMicro Cap
- $24.10m
- $26.03m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 0.851 | 1.94 | 2.05 | 3.13 |
Operating Profit | -0.851 | -1.94 | -2.05 | -3.13 |
Net Income Before Taxes | -0.851 | -1.94 | -2.05 | -3.13 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.851 | -1.94 | -2.05 | -3.13 |
Minority Interest | ||||
Net Income Before Extraordinary Items | ||||
Net Income | -0.851 | -1.94 | -2.05 | -3.13 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.851 | -1.94 | -2.05 | -3.13 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.078 | -0.179 | -0.188 | -0.272 |
Dividends per Share |